EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer

PURPOSE: Evaluating consecutive early breast cancer patients, we analyzed both the impact of EndoPredict(®) on clinical decisions as well as clinico-pathological factors influencing the decision to perform this gene expression test. METHODS: Hormone receptor (HR)-positive and human epidermal growth...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Almstedt, K., Mendoza, S., Otto, M., Battista, M. J., Steetskamp, J., Heimes, A. S., Krajnak, S., Poplawski, A., Gerhold-Ay, A., Hasenburg, A., Denkert, C., Schmidt, M.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2020
Matèries:
Clinical Trial
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7275019/
https://ncbi.nlm.nih.gov/pubmed/32436145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05688-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars